Atea Pharmaceuticals Analyst Ratings
Atea Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/27/2023 | 31.29% | SVB Leerink | $8 → $6 | Maintains | Market Perform |
| 01/24/2023 | -12.47% | Morgan Stanley | $7 → $4 | Maintains | Underweight |
| 08/15/2022 | 53.17% | Morgan Stanley | $6 → $7 | Maintains | Underweight |
| 03/02/2022 | 75.05% | JP Morgan | $10 → $8 | Maintains | Neutral |
| 03/01/2022 | 96.94% | SVB Leerink | $10 → $9 | Maintains | Market Perform |
| 02/16/2022 | 118.82% | SVB Leerink | $11 → $10 | Maintains | Market Perform |
| 01/06/2022 | 53.17% | Morgan Stanley | $14 → $7 | Downgrades | Equal-Weight → Underweight |
| 11/18/2021 | 140.7% | SVB Leerink | → $11 | Downgrades | Outperform → Market Perform |
| 10/20/2021 | 337.64% | SVB Leerink | $60 → $20 | Maintains | Outperform |
| 10/20/2021 | 250.11% | JP Morgan | $61 → $16 | Downgrades | Overweight → Neutral |
| 10/05/2021 | 1103.5% | Morgan Stanley | → $55 | Downgrades | Overweight → Equal-Weight |
| 09/09/2021 | 1212.91% | SVB Leerink | → $60 | Initiates Coverage On | → Outperform |
| 08/18/2021 | 709.63% | Morgan Stanley | $35 → $37 | Maintains | Overweight |
| 06/03/2021 | 665.86% | Morgan Stanley | $82 → $35 | Maintains | Overweight |
| 04/06/2021 | 1694.31% | Morgan Stanley | $49 → $82 | Maintains | Overweight |
| 01/29/2021 | 1344.2% | JP Morgan | $45 → $66 | Maintains | Overweight |
| 11/25/2020 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 884.68% | JP Morgan | → $45 | Initiates Coverage On | → Overweight |
| 11/24/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 972.21% | Morgan Stanley | → $49 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年1月27日 | 31.29% | SVB Leerink | $8→$6 | 维护 | 市场表现 |
| 01/24/2023 | -12.47% | 摩根士丹利 | $7→$4 | 维护 | 体重不足 |
| 2022年08月15日 | 53.17% | 摩根士丹利 | $6→$7 | 维护 | 体重不足 |
| 03/02/2022 | 75.05% | 摩根大通 | $10→$8 | 维护 | 中性 |
| 03/01/2022 | 96.94% | SVB Leerink | $10→$9 | 维护 | 市场表现 |
| 02/16/2022 | 118.82% | SVB Leerink | $11→$10 | 维护 | 市场表现 |
| 01/06/2022 | 53.17% | 摩根士丹利 | $14→$7 | 评级下调 | 等重→减码 |
| 2021年11月18日 | 140.7% | SVB Leerink | →$11 | 评级下调 | 跑赢→市场表现 |
| 10/20/2021 | 337.64% | SVB Leerink | $60→$20 | 维护 | 跑赢大盘 |
| 10/20/2021 | 250.11% | 摩根大通 | $61→$16 | 评级下调 | 超重→中性 |
| 10/05/2021 | 1103.5% | 摩根士丹利 | →$55 | 评级下调 | 超重→等重 |
| 09/09/2021 | 1212.91% | SVB Leerink | →$60 | 开始承保 | →跑赢大盘 |
| 2021/08/18 | 709.63% | 摩根士丹利 | $35→$37 | 维护 | 超重 |
| 06/03/2021 | 665.86% | 摩根士丹利 | $82→$35 | 维护 | 超重 |
| 04/06/2021 | 1694.31% | 摩根士丹利 | $49→$82 | 维护 | 超重 |
| 2021/01/29 | 1344.2% | 摩根大通 | $45→$66 | 维护 | 超重 |
| 11/25/2020 | - | Evercore ISI集团 | 开始承保 | →跑赢大盘 | |
| 11/24/2020 | 884.68% | 摩根大通 | →$45 | 开始承保 | →超重 |
| 11/24/2020 | - | 威廉·布莱尔 | 开始承保 | →跑赢大盘 | |
| 11/24/2020 | 972.21% | 摩根士丹利 | →$49 | 开始承保 | →超重 |
What is the target price for Atea Pharmaceuticals (AVIR)?
ATEA制药(Avir)的目标价是多少？
The latest price target for Atea Pharmaceuticals (NASDAQ: AVIR) was reported by SVB Leerink on January 27, 2023. The analyst firm set a price target for $6.00 expecting AVIR to rise to within 12 months (a possible 31.29% upside). 6 analyst firms have reported ratings in the last year.
ATEA制药(纳斯达克：AVIR)的最新目标价是由SVB Leerink于2023年1月27日报道的。这家分析公司将目标价定为6.00美元，预计Avir将在12个月内上涨(可能上涨31.29%)。6家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Atea Pharmaceuticals (AVIR)?
分析师对安泰制药(AVIR)的最新评级是多少？
The latest analyst rating for Atea Pharmaceuticals (NASDAQ: AVIR) was provided by SVB Leerink, and Atea Pharmaceuticals maintained their market perform rating.
ATEA制药(纳斯达克代码：AVIR)的最新分析师评级由SVB Leerink提供，ATEA制药维持其市场表现评级。
When is the next analyst rating going to be posted or updated for Atea Pharmaceuticals (AVIR)?
安泰制药(Avir)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atea Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atea Pharmaceuticals was filed on January 27, 2023 so you should expect the next rating to be made available sometime around January 27, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与ATEA制药公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。对ATEA制药的上一次评级是在2023年1月27日提交的，所以你应该预计下一次评级将在2024年1月27日左右的某个时候公布。
Is the Analyst Rating Atea Pharmaceuticals (AVIR) correct?
分析师对安泰制药(AVIR)的评级正确吗？
While ratings are subjective and will change, the latest Atea Pharmaceuticals (AVIR) rating was a maintained with a price target of $8.00 to $6.00. The current price Atea Pharmaceuticals (AVIR) is trading at is $4.57, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的ATEA制药(Avir)评级维持不变，目标价在8.00美元至6.00美元之间。ATEA制药(Avir)目前的交易价格为4.57美元，超出了分析师的预测区间。